Raj Wadwa
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 120 | 2024 | 3360 | 8.990 |
Why?
| Insulin Infusion Systems | 39 | 2023 | 304 | 4.700 |
Why?
| Blood Glucose | 63 | 2024 | 1939 | 3.950 |
Why?
| Insulin | 44 | 2023 | 2162 | 3.360 |
Why?
| Hypoglycemic Agents | 43 | 2023 | 1032 | 3.280 |
Why?
| Blood Glucose Self-Monitoring | 38 | 2024 | 534 | 3.020 |
Why?
| Hypoglycemia | 25 | 2023 | 400 | 2.420 |
Why?
| Pancreas, Artificial | 16 | 2021 | 71 | 2.110 |
Why?
| Diabetic Angiopathies | 16 | 2019 | 260 | 1.780 |
Why?
| Vascular Stiffness | 14 | 2019 | 425 | 1.690 |
Why?
| Cardiovascular Diseases | 25 | 2019 | 1798 | 1.660 |
Why?
| Adolescent | 94 | 2024 | 18480 | 1.430 |
Why?
| Child | 72 | 2024 | 19129 | 1.160 |
Why?
| Telemedicine | 3 | 2022 | 664 | 1.040 |
Why?
| Albuminuria | 4 | 2019 | 195 | 0.990 |
Why?
| Diabetes Mellitus, Type 2 | 11 | 2020 | 2174 | 0.990 |
Why?
| Young Adult | 52 | 2023 | 10793 | 0.920 |
Why?
| Hyperglycemia | 11 | 2022 | 312 | 0.910 |
Why?
| Dyslipidemias | 4 | 2019 | 162 | 0.810 |
Why?
| Humans | 134 | 2024 | 118972 | 0.810 |
Why?
| Male | 92 | 2024 | 57801 | 0.770 |
Why?
| Biosensing Techniques | 2 | 2020 | 107 | 0.760 |
Why?
| Female | 94 | 2024 | 61564 | 0.750 |
Why?
| Uromodulin | 1 | 2019 | 28 | 0.690 |
Why?
| Glycopeptides | 1 | 2019 | 58 | 0.680 |
Why?
| Carotid Intima-Media Thickness | 3 | 2018 | 68 | 0.620 |
Why?
| Insulin Lispro | 4 | 2022 | 35 | 0.610 |
Why?
| Biomarkers | 10 | 2020 | 3588 | 0.590 |
Why?
| Ketones | 2 | 2016 | 45 | 0.590 |
Why?
| Child, Preschool | 19 | 2023 | 9491 | 0.570 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 387 | 0.560 |
Why?
| Autonomic Nervous System | 3 | 2013 | 66 | 0.540 |
Why?
| Cholesterol | 6 | 2020 | 373 | 0.530 |
Why?
| Adult | 53 | 2024 | 31512 | 0.530 |
Why?
| Remote Consultation | 1 | 2015 | 39 | 0.520 |
Why?
| Diabetic Nephropathies | 5 | 2019 | 289 | 0.500 |
Why?
| Patient Compliance | 2 | 2015 | 537 | 0.490 |
Why?
| Monitoring, Ambulatory | 4 | 2020 | 84 | 0.450 |
Why?
| Cystatin C | 2 | 2015 | 69 | 0.440 |
Why?
| Diagnostic Techniques, Cardiovascular | 2 | 2014 | 12 | 0.440 |
Why?
| Calcinosis | 4 | 2014 | 282 | 0.440 |
Why?
| Patient Education as Topic | 4 | 2019 | 699 | 0.440 |
Why?
| Case-Control Studies | 13 | 2020 | 3171 | 0.420 |
Why?
| Glucagon | 3 | 2016 | 97 | 0.410 |
Why?
| Risk Factors | 27 | 2019 | 9000 | 0.410 |
Why?
| Triglycerides | 9 | 2022 | 519 | 0.400 |
Why?
| Reproducibility of Results | 9 | 2024 | 2874 | 0.400 |
Why?
| Diabetic Ketoacidosis | 5 | 2022 | 168 | 0.390 |
Why?
| Insulin Aspart | 3 | 2022 | 26 | 0.390 |
Why?
| Arteries | 2 | 2010 | 250 | 0.390 |
Why?
| Algorithms | 11 | 2022 | 1541 | 0.390 |
Why?
| Quality of Life | 5 | 2022 | 2366 | 0.380 |
Why?
| Self-Management | 2 | 2023 | 136 | 0.380 |
Why?
| Graves Disease | 1 | 2010 | 32 | 0.370 |
Why?
| Adipose Tissue | 3 | 2022 | 606 | 0.360 |
Why?
| Friedreich Ataxia | 1 | 2010 | 64 | 0.350 |
Why?
| Cholesterol, LDL | 4 | 2014 | 316 | 0.340 |
Why?
| Middle Aged | 32 | 2023 | 27617 | 0.340 |
Why?
| Glomerular Filtration Rate | 4 | 2019 | 683 | 0.330 |
Why?
| Psychometrics | 3 | 2021 | 631 | 0.330 |
Why?
| Diabetes Complications | 2 | 2007 | 218 | 0.320 |
Why?
| Skiing | 2 | 2019 | 39 | 0.320 |
Why?
| Vascular Diseases | 2 | 2013 | 241 | 0.320 |
Why?
| Pulse Wave Analysis | 10 | 2019 | 216 | 0.310 |
Why?
| Hyperlipidemias | 2 | 2007 | 128 | 0.310 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1440 | 0.310 |
Why?
| Insulin Resistance | 6 | 2019 | 1180 | 0.280 |
Why?
| Calibration | 4 | 2019 | 135 | 0.280 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.270 |
Why?
| Coronary Artery Disease | 3 | 2007 | 647 | 0.270 |
Why?
| Exercise | 5 | 2019 | 1657 | 0.260 |
Why?
| Self Report | 2 | 2020 | 699 | 0.260 |
Why?
| Apolipoproteins B | 1 | 2014 | 44 | 0.260 |
Why?
| Blood Pressure | 7 | 2014 | 1664 | 0.250 |
Why?
| Heart Rate | 5 | 2019 | 729 | 0.240 |
Why?
| Infusion Pumps, Implantable | 2 | 2020 | 20 | 0.240 |
Why?
| Pilot Projects | 2 | 2020 | 1419 | 0.230 |
Why?
| Body Mass Index | 10 | 2020 | 2092 | 0.230 |
Why?
| Adiponectin | 4 | 2012 | 226 | 0.230 |
Why?
| Diabetic Neuropathies | 3 | 2019 | 78 | 0.220 |
Why?
| Blood Vessels | 2 | 2018 | 187 | 0.220 |
Why?
| Kidney | 3 | 2022 | 1353 | 0.210 |
Why?
| Cholesterol, HDL | 4 | 2014 | 198 | 0.210 |
Why?
| Lipids | 3 | 2014 | 607 | 0.210 |
Why?
| Insulin, Regular, Human | 4 | 2023 | 32 | 0.210 |
Why?
| Hypertension | 4 | 2019 | 1203 | 0.200 |
Why?
| Computer Systems | 2 | 2018 | 47 | 0.200 |
Why?
| Uric Acid | 2 | 2015 | 354 | 0.200 |
Why?
| Age Factors | 9 | 2016 | 2995 | 0.200 |
Why?
| Adiposity | 2 | 2018 | 516 | 0.200 |
Why?
| Technology | 1 | 2022 | 83 | 0.200 |
Why?
| Cross-Over Studies | 6 | 2019 | 456 | 0.190 |
Why?
| Cohort Studies | 11 | 2017 | 5116 | 0.190 |
Why?
| Glycosides | 1 | 2021 | 34 | 0.190 |
Why?
| Guideline Adherence | 2 | 2015 | 523 | 0.190 |
Why?
| Adolescent Behavior | 2 | 2017 | 482 | 0.190 |
Why?
| Microvessels | 2 | 2018 | 77 | 0.190 |
Why?
| Inpatients | 1 | 2024 | 388 | 0.180 |
Why?
| Patient Dropouts | 1 | 2020 | 66 | 0.180 |
Why?
| Prevalence | 6 | 2014 | 2326 | 0.180 |
Why?
| Sports | 2 | 2019 | 194 | 0.180 |
Why?
| Coronary Vessels | 2 | 2014 | 233 | 0.180 |
Why?
| Carotid Arteries | 2 | 2013 | 184 | 0.170 |
Why?
| Brachial Artery | 3 | 2016 | 181 | 0.170 |
Why?
| Administration, Intranasal | 2 | 2016 | 79 | 0.170 |
Why?
| Treatment Outcome | 11 | 2022 | 9342 | 0.170 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 693 | 0.170 |
Why?
| Bacterial Vaccines | 1 | 1999 | 60 | 0.170 |
Why?
| Follow-Up Studies | 8 | 2019 | 4596 | 0.170 |
Why?
| Antihypertensive Agents | 3 | 2014 | 437 | 0.160 |
Why?
| Pneumococcal Infections | 1 | 1999 | 96 | 0.160 |
Why?
| Cardiotonic Agents | 1 | 2018 | 127 | 0.160 |
Why?
| Biomedical Technology | 1 | 2018 | 43 | 0.160 |
Why?
| Infant | 7 | 2019 | 8293 | 0.160 |
Why?
| Transplantation Conditioning | 1 | 2019 | 156 | 0.160 |
Why?
| Streptococcus pneumoniae | 1 | 1999 | 141 | 0.160 |
Why?
| Endocrinology | 1 | 2018 | 68 | 0.160 |
Why?
| Ohio | 5 | 2015 | 141 | 0.150 |
Why?
| Diabetic Cardiomyopathies | 2 | 2016 | 39 | 0.150 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.150 |
Why?
| Aged | 12 | 2023 | 19657 | 0.150 |
Why?
| Sex Factors | 5 | 2016 | 1781 | 0.150 |
Why?
| Regression Analysis | 4 | 2014 | 983 | 0.150 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 60 | 0.140 |
Why?
| Cross-Sectional Studies | 7 | 2017 | 4552 | 0.140 |
Why?
| Risk Assessment | 4 | 2014 | 3057 | 0.140 |
Why?
| Immunization | 1 | 1999 | 412 | 0.140 |
Why?
| Aorta | 1 | 2018 | 367 | 0.140 |
Why?
| Wyoming | 1 | 2015 | 17 | 0.140 |
Why?
| Surveys and Questionnaires | 7 | 2021 | 4708 | 0.140 |
Why?
| Perception | 1 | 2018 | 314 | 0.130 |
Why?
| Colorado | 9 | 2017 | 4196 | 0.130 |
Why?
| Coronary Disease | 3 | 2007 | 356 | 0.130 |
Why?
| Inflammation | 2 | 2018 | 2566 | 0.130 |
Why?
| Periodontal Diseases | 1 | 2015 | 58 | 0.130 |
Why?
| Pediatric Obesity | 2 | 2019 | 524 | 0.130 |
Why?
| Lipoproteins | 2 | 2022 | 162 | 0.130 |
Why?
| Videoconferencing | 1 | 2015 | 59 | 0.130 |
Why?
| Hormones | 1 | 2015 | 135 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2022 | 867 | 0.130 |
Why?
| Metformin | 1 | 2018 | 295 | 0.130 |
Why?
| Hospitalization | 1 | 2024 | 1785 | 0.130 |
Why?
| Self Care | 2 | 2014 | 357 | 0.130 |
Why?
| Sleep | 2 | 2022 | 660 | 0.120 |
Why?
| Atherosclerosis | 3 | 2015 | 345 | 0.120 |
Why?
| Patient Satisfaction | 1 | 2018 | 610 | 0.120 |
Why?
| Vascular Calcification | 1 | 2016 | 123 | 0.120 |
Why?
| Ketosis | 1 | 2014 | 13 | 0.120 |
Why?
| Pandemics | 1 | 2022 | 1355 | 0.120 |
Why?
| Circadian Rhythm | 2 | 2015 | 401 | 0.120 |
Why?
| Creatinine | 2 | 2015 | 491 | 0.120 |
Why?
| Dietary Fiber | 1 | 2014 | 44 | 0.120 |
Why?
| Parents | 4 | 2022 | 1212 | 0.120 |
Why?
| Goals | 1 | 2015 | 167 | 0.120 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 540 | 0.120 |
Why?
| Pediatrics | 2 | 2018 | 985 | 0.110 |
Why?
| Monitoring, Physiologic | 1 | 2015 | 271 | 0.110 |
Why?
| Bionics | 2 | 2022 | 11 | 0.110 |
Why?
| Prognosis | 6 | 2020 | 3443 | 0.110 |
Why?
| Acetaminophen | 1 | 2015 | 244 | 0.110 |
Why?
| Registries | 3 | 2020 | 1810 | 0.110 |
Why?
| Longitudinal Studies | 6 | 2016 | 2513 | 0.110 |
Why?
| Femoral Artery | 1 | 2013 | 175 | 0.110 |
Why?
| Obesity | 3 | 2020 | 2746 | 0.100 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 162 | 0.100 |
Why?
| Kidney Function Tests | 1 | 2011 | 164 | 0.100 |
Why?
| Precision Medicine | 1 | 2014 | 363 | 0.090 |
Why?
| Thyroidectomy | 1 | 2010 | 54 | 0.090 |
Why?
| Injections, Subcutaneous | 2 | 2020 | 138 | 0.090 |
Why?
| Vitamin D | 1 | 2013 | 354 | 0.090 |
Why?
| Infant, Newborn | 4 | 2019 | 5255 | 0.090 |
Why?
| Hypolipidemic Agents | 2 | 2008 | 86 | 0.090 |
Why?
| United States | 8 | 2020 | 12555 | 0.090 |
Why?
| Outpatients | 3 | 2021 | 325 | 0.090 |
Why?
| Blood Flow Velocity | 2 | 2010 | 327 | 0.090 |
Why?
| Glycosuria | 1 | 2009 | 8 | 0.090 |
Why?
| Diabetes Mellitus | 3 | 2018 | 942 | 0.080 |
Why?
| Double-Blind Method | 3 | 2021 | 1687 | 0.080 |
Why?
| Consensus | 2 | 2023 | 534 | 0.080 |
Why?
| Combined Modality Therapy | 3 | 2017 | 1166 | 0.080 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| Life Style | 2 | 2008 | 430 | 0.080 |
Why?
| Mobile Applications | 2 | 2020 | 147 | 0.080 |
Why?
| Cold Temperature | 2 | 2019 | 132 | 0.080 |
Why?
| Age Distribution | 2 | 2006 | 362 | 0.080 |
Why?
| Equipment Design | 2 | 2019 | 519 | 0.080 |
Why?
| Meals | 2 | 2019 | 101 | 0.080 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 969 | 0.080 |
Why?
| Radionuclide Imaging | 1 | 2007 | 124 | 0.080 |
Why?
| Health Promotion | 1 | 2014 | 691 | 0.080 |
Why?
| Disease Progression | 5 | 2018 | 2490 | 0.080 |
Why?
| Catheter Ablation | 1 | 2010 | 286 | 0.070 |
Why?
| Fetal Distress | 1 | 2006 | 13 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 82 | 0.070 |
Why?
| Time Factors | 3 | 2014 | 6412 | 0.070 |
Why?
| Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| Smoking | 1 | 2014 | 1487 | 0.070 |
Why?
| Polymorphism, Genetic | 2 | 2007 | 642 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 195 | 0.070 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 70 | 0.070 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1384 | 0.070 |
Why?
| Seasons | 2 | 2019 | 461 | 0.070 |
Why?
| Postprandial Period | 2 | 2018 | 96 | 0.070 |
Why?
| Hypertrophy | 2 | 2016 | 121 | 0.070 |
Why?
| Family Health | 1 | 2006 | 201 | 0.070 |
Why?
| Pregnancy in Diabetics | 1 | 2006 | 88 | 0.070 |
Why?
| Linear Models | 3 | 2014 | 827 | 0.060 |
Why?
| Infant, Newborn, Diseases | 1 | 2006 | 106 | 0.060 |
Why?
| Feasibility Studies | 2 | 2018 | 749 | 0.060 |
Why?
| Radiography | 1 | 2007 | 861 | 0.060 |
Why?
| Hair | 1 | 2004 | 68 | 0.060 |
Why?
| Glucose Intolerance | 1 | 2005 | 139 | 0.060 |
Why?
| Sex Distribution | 1 | 2005 | 351 | 0.060 |
Why?
| Cotinine | 1 | 2004 | 76 | 0.060 |
Why?
| Prospective Studies | 3 | 2022 | 6471 | 0.060 |
Why?
| Hemodynamics | 2 | 2022 | 1003 | 0.060 |
Why?
| Rats | 1 | 2012 | 5392 | 0.060 |
Why?
| Seizures | 1 | 2006 | 345 | 0.060 |
Why?
| Stroke | 1 | 2012 | 1047 | 0.060 |
Why?
| Inflammation Mediators | 1 | 2006 | 502 | 0.060 |
Why?
| Incidence | 3 | 2014 | 2424 | 0.060 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2022 | 17 | 0.060 |
Why?
| Glucose | 2 | 2021 | 953 | 0.060 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1868 | 0.060 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 369 | 0.060 |
Why?
| Societies, Medical | 2 | 2018 | 703 | 0.060 |
Why?
| Reference Values | 2 | 2018 | 774 | 0.050 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 233 | 0.050 |
Why?
| Insulin-Secreting Cells | 1 | 2005 | 330 | 0.050 |
Why?
| Motor Activity | 2 | 2018 | 660 | 0.050 |
Why?
| Sitosterols | 1 | 2020 | 1 | 0.050 |
Why?
| Behavior Therapy | 1 | 2023 | 237 | 0.050 |
Why?
| Phytosterols | 1 | 2020 | 9 | 0.050 |
Why?
| Environmental Exposure | 1 | 2004 | 405 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 70 | 0.050 |
Why?
| Logistic Models | 1 | 2005 | 1901 | 0.050 |
Why?
| Pancreas | 1 | 2022 | 282 | 0.050 |
Why?
| Social Conditions | 1 | 2019 | 13 | 0.050 |
Why?
| India | 1 | 2020 | 141 | 0.050 |
Why?
| Autonomic Nervous System Diseases | 1 | 2019 | 28 | 0.040 |
Why?
| Fear | 1 | 2022 | 307 | 0.040 |
Why?
| Factor Analysis, Statistical | 1 | 2020 | 270 | 0.040 |
Why?
| Personal Satisfaction | 1 | 2021 | 188 | 0.040 |
Why?
| Vaccines, Conjugate | 1 | 1999 | 63 | 0.040 |
Why?
| Retrospective Studies | 5 | 2014 | 12978 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 194 | 0.040 |
Why?
| Smartphone | 1 | 2019 | 67 | 0.040 |
Why?
| Waist Circumference | 1 | 2018 | 130 | 0.040 |
Why?
| International Cooperation | 1 | 2018 | 177 | 0.040 |
Why?
| Accelerometry | 1 | 2018 | 72 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 965 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 191 | 0.040 |
Why?
| Virginia | 1 | 2017 | 52 | 0.040 |
Why?
| Sex Characteristics | 2 | 2017 | 671 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2023 | 1244 | 0.040 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 218 | 0.040 |
Why?
| Age of Onset | 1 | 2018 | 467 | 0.040 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 210 | 0.040 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 98 | 0.040 |
Why?
| Vascular Capacitance | 1 | 2016 | 4 | 0.040 |
Why?
| Powders | 1 | 2016 | 37 | 0.030 |
Why?
| Family | 1 | 2020 | 585 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2019 | 681 | 0.030 |
Why?
| Food Preferences | 1 | 2017 | 119 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 3174 | 0.030 |
Why?
| Equipment Failure | 1 | 2016 | 114 | 0.030 |
Why?
| Nausea | 1 | 2016 | 107 | 0.030 |
Why?
| Injections, Intramuscular | 1 | 2016 | 116 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2018 | 306 | 0.030 |
Why?
| Ankle Brachial Index | 1 | 2015 | 30 | 0.030 |
Why?
| Child Behavior | 1 | 2017 | 212 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 230 | 0.030 |
Why?
| International Agencies | 1 | 2014 | 29 | 0.030 |
Why?
| Apolipoproteins | 1 | 2014 | 39 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 175 | 0.030 |
Why?
| Program Evaluation | 1 | 2019 | 845 | 0.030 |
Why?
| Societies, Scientific | 1 | 2014 | 49 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2015 | 536 | 0.030 |
Why?
| Patient Care Team | 1 | 2019 | 521 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 354 | 0.030 |
Why?
| Adolescent Medicine | 1 | 2014 | 35 | 0.030 |
Why?
| China | 1 | 2014 | 175 | 0.030 |
Why?
| Pressure | 1 | 2014 | 226 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 58 | 0.030 |
Why?
| Risk | 1 | 2016 | 853 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 245 | 0.030 |
Why?
| Fibrinogen | 1 | 2014 | 161 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 185 | 0.030 |
Why?
| Feeding Behavior | 1 | 2018 | 601 | 0.030 |
Why?
| Diabetic Retinopathy | 1 | 2014 | 160 | 0.030 |
Why?
| American Heart Association | 1 | 2014 | 270 | 0.030 |
Why?
| Up-Regulation | 1 | 2015 | 872 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1945 | 0.030 |
Why?
| Quality Improvement | 1 | 2019 | 963 | 0.020 |
Why?
| Genotype | 2 | 2007 | 1882 | 0.020 |
Why?
| Animals | 1 | 2012 | 33381 | 0.020 |
Why?
| Pulsatile Flow | 1 | 2010 | 54 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1200 | 0.020 |
Why?
| Elasticity | 1 | 2010 | 193 | 0.020 |
Why?
| Arm | 1 | 2010 | 106 | 0.020 |
Why?
| South Carolina | 1 | 2008 | 38 | 0.020 |
Why?
| Lipoproteins, HDL | 1 | 2008 | 82 | 0.020 |
Why?
| Nutrition Therapy | 1 | 2008 | 32 | 0.020 |
Why?
| Models, Biological | 1 | 2015 | 1715 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2008 | 138 | 0.020 |
Why?
| Leg | 1 | 2010 | 234 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 11 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| Pancreatic Function Tests | 1 | 2005 | 4 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 276 | 0.020 |
Why?
| C-Peptide | 1 | 2005 | 137 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2436 | 0.020 |
Why?
| Glucose Tolerance Test | 1 | 2005 | 368 | 0.020 |
Why?
| Mother-Child Relations | 1 | 2004 | 109 | 0.010 |
Why?
| Population Surveillance | 1 | 2006 | 413 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2008 | 907 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1178 | 0.010 |
Why?
| DNA | 1 | 2006 | 1388 | 0.010 |
Why?
| Pregnancy | 1 | 2006 | 5690 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|